Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis

Affiliations

¹ Department of Dermatology, Rouen University Hospital, Rouen, France. Electronic address: billal.tedbirt@etu.univ-rouen.fr.
² Department of Dermatology, Caen University Hospital, Caen, France.
³ Department of Neurology, Caen University Hospital, Caen, France.
⁴ Department of Dermatology, APHP Saint Louis Hospital, Paris, France.
⁵ Department of Dermatology, APHP Saint Louis Hospital, Paris, France; Université Paris 7 Diderot, Sorbonne Paris Cité, Paris, France.
⁶ Université Paris 7 Diderot, Sorbonne Paris Cité, Paris, France; Department of Neurooncology, APHP Saint Louis Hospital, Paris, France.

Comment

Billal Tedbirt et al. Eur J Cancer. 2019 May.

. 2019 May:113:72-74.

doi: 10.1016/j.ejca.2019.03.006. Epub 2019 Apr 12.

¹ Department of Dermatology, Rouen University Hospital, Rouen, France. Electronic address: billal.tedbirt@etu.univ-rouen.fr.
² Department of Dermatology, Caen University Hospital, Caen, France.
³ Department of Neurology, Caen University Hospital, Caen, France.
⁴ Department of Dermatology, APHP Saint Louis Hospital, Paris, France.
⁵ Department of Dermatology, APHP Saint Louis Hospital, Paris, France; Université Paris 7 Diderot, Sorbonne Paris Cité, Paris, France.
⁶ Université Paris 7 Diderot, Sorbonne Paris Cité, Paris, France; Department of Neurooncology, APHP Saint Louis Hospital, Paris, France.

No abstract available

Comment on

Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.
Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mitzel-Rink H, Schuler G, Terheyden P, Thoms KM, Türk M, Dummer R, Zimmer L, Schröder R, Heinzerling L. Moreira A, et al. Eur J Cancer. 2019 Jan;106:12-23. doi: 10.1016/j.ejca.2018.09.033. Epub 2018 Nov 17. Eur J Cancer. 2019. PMID: 30453170